TEVA PHARMACEUTICAL INDUSTRIES LTD 8-K

What Happened

• On April 29, 2026, Teva Pharmaceutical Industries Ltd. filed a Current Report on Form 8‑K furnishing press releases announcing its financial results for the quarter ended March 31, 2026 and announcing that it has entered into a definitive agreement to acquire Emalex Biosciences. The press releases are furnished as Exhibit 99.1 (Q1 2026 results) and Exhibit 99.2 (acquisition announcement).

Key Details

• Filing date: April 29, 2026; quarter covered: ended March 31, 2026.
• Press releases furnished as Exhibit 99.1 (Q1 results) and Exhibit 99.2 (to acquire Emalex Biosciences).
• The Form 8‑K states the furnished information is not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference except where expressly stated.
• Interactive XBRL cover page included as Exhibit 104.

Why It Matters

• The earnings press release provides Teva’s quarterly results (revenue, profitability and operating trends) that investors use to assess near‑term performance; review the Exhibit 99.1 press release for the specific numbers.
• The announced definitive agreement to acquire Emalex Biosciences is a material corporate development that could affect Teva’s product pipeline or strategic direction; the press release (Exhibit 99.2) and any subsequent SEC filings should be consulted for deal terms and financial impact.
• Investors should read the furnished exhibits and watch for follow‑up filings that disclose transaction specifics, financial effects, or additional material information.